Cardio3 BioSciences (C3BS) has announced the appointment of Dr. Alexander Milstein as Vice President of Clinical Development.
Dr. Milstein brings to the Company extensive industry experience, including leading the design and execution of global clinical strategies for product approvals and competitive positioning of medical devices, drug-device combinations, and cell therapies worldwide.
His expertise in clinical trial design and his ability to drive clinical development programs towards regulatory approvals have earned him recognition among peers and regulators internationally.
Prior to joining C3BS Dr. Milstein held the position of Vice President, Clinical Development at Cytori Therapeutics.
Dr. Milstein has also held senior and management positions at Medtronic Corporation, Guidant Corporation, and Acusphere Inc. His work included all aspects and stages of clinical development, successful collaboration with key opinion leaders and extensive interactions with regulators in the US, Europe, and Asia-Pacific.
Dr. Milstein started his career in clinical development as a research fellow with Harvard University and Massachusetts General Hospital. He holds a medical degree from the Moscow Medical University.
Dr. Alexander Milstein, VP of Clinical Development, said: “Cardio3 BioSciences’ pipeline holds great therapeutic potential for significant, currently unmet medical needs. I am pleased and excited to have the opportunity to join Cardio3 BioSciences and lead the execution of an effective and successful clinical development program for C3BS-CQR-1 which will enter Phase III in 2012, as well as advancing the company’s other products into clinical development.”